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doi:10.1016/j.jmii.2011.11.004Background/Purpose: Human papillomavirus (HPV) infection can cause laryngeal papillomas in
children. Vertical transmission has been confirmed. This study aimed to establish a sensitive
molecular diagnostic method and understand the incidence of the HPV-6 and HPV-11 in
neonates with intubation.
Methods: We enrolled 108 newborns between October 2007 and January 2010. All neonates
were intubated due to underlying disease. The specimens were collected via endotracheal
aspiration. DNA of HPV types 6 and 11 was detected by real-time PCR and nested PCR.
Results: HPV-DNA was detected in eight of the 108 newborns studied. Seven respiratory spec-
imens tested positive for HPV-11 and one was positive for HPV-6. The HPV 6/11 detection rate
in neonates was 7.4% (8/108).
Conclusion: A rapid, sensitive, specific, and reproducible RT-PCR method and nest PCR were
developed for the detection and differentiation of HPV-6 and HPV-11 genomic variants in
a single PCR reaction. The assays are of great value for clinical and epidemiologic studies of
HPV-6 and HPV-11 infections. Neonatal HPV colonization may be related to juvenile-onset
recurrent respiratory papillomatosis. The transmission route may be from mother to child.
The clinical significance of neonatal carriage of HPV-6 or HPV-11 warrants further study.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
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186 C.-F. Tai et al.Introduction most children with RRP were born to mothers who hadHuman papillomavirus (HPV) is a well-known cause of
anogenital warts and cervical cancer. In children, HPV is
associated with laryngeal and conjunctival papillomas.1,2
HPV is mainly transmitted through sexual routes, but
nonsexual route transmission is also possible.3 This includes
motherechild transmission during the perinatal period and
casual physical contact.4 Vertical transmission may occur
when an infant passes through an infected birth canal,
through ascending infection, at the time of sperm fertil-
ization, or hematogenously.3,5,6 However, these observa-
tions have yet to be well-established.
HPV-6 and 11 are responsible for recurrent respiratory
papillomatosis (RRP), a disease with a peak incidence
between 2 and 4 years of age.7 Several studies showed thatFigure 1. Alignment of HPV6 and HPV11 E6 genes. The figure sho
number: FM897037, FM875943, FM875980, PPH11, EU918768, >PPHL
of HPV 6 and 11. The thin black arrows point to the specific sequehistory of genital condylomata based on clinical observa-
tion.8e10 This cross-section and prospective study aimed to
evaluate the incidence of HPV in newborns with intubation.
We used the molecular method to detect the tracheal aspi-
rate of neonates and discussed the risk of RRP in neonates
with HPV colonization.Patients and methods
Population
Between October 2007 and January 2010, 108 neonates were
enrolled in National Taiwan University Hospital. The Taiwan
Association of institutional review board had approvedws the E6 gene sequence of HPV 6 and 11 (GenBank accession
1E671V). The thick black arrows point to the common sequence
nce of HPV6 and 11.
Table 1 Primers sequence used for real-time PCR detec-
tion of HPV 6 and 11 types
Target type Sequence
HPV 6 Forward:
E6-159 50-CCTgTTTCgAggCggCTATCCAT-30
Reverse:
E6-377 50-ACCgTgCCTTggTTAgTATATgT-30
HPV 11 Forward:
E6-159 50-TgTgTggCgAgACAACTTTCCCTT-30
Reverse:
E6-377 50-gCgTgCCTTTCCCAATATgTgC-30
Molecular detection/epidemiology of HPV in neonates 187the research. All parents signed an informed consent form
before their childrenwere entered into the study. All neonates
were younger than 30 days of age and had been intubated due
to underlying illness (such as congenital heart disease, prema-
turity, respiratorydistress,andperinatalasphyxia).Respiratory
specimens were collected by tracheal aspiration through an
endotracheal tube.Neonatal gestational age, comorbidity, and
maternal HPV status were not studied in this study.
Specimens
Before specimens were collected, a chest X-ray was per-
formed to confirm that the endotracheal tube was positioned
properly. A 6.5 French sterile suction catheter was thenFigure 2. The standard curve of HPV6 real-time PCR. Amplificat
4 107, 4 106, 4 105, 4 104, 4 103, 4 102, and 4 101 vira
dependent on the PCR cycle number on the x-axis.inserted through the endotracheal tube. One-3 mL room-
temperature 0.9% saline was installed and aspirated back
into a collecting chamber. Warm saline was used instead for
neonateswithvery lowbirthweight.Theaboveprocedurewas
repeated three consecutive times if tolerated. The specimen
was then kept frozen at e80C until DNA could be extracted.
Laboratory methods
Virus and nucleic acid extraction
Nucleic acid was extracted from tracheal aspirates using
a MagNA Pure LC 2.0 instrument (Roche Molecular,
Mannheim, Germany).
Real-time PCR conditions
DNA of HPV-6 and 11 was detected by real-time polymerase
chain reaction (PCR) using HPV type-specific primers based
on the HPV E6 genes (quantitative HPV type-specific PCR).
The sequences were retrieved from GenBank (Fig. 1).
Primers sequences for the HPV-6 were E6-159F 50-CCTg-
TTTCgAggCggCTATCCAT-30 and E6-377R 50-ACCgTgCCTTgg-
TTAgTATATgT-30. The primers of HPV-11 were E6-159F
50-TgTgTggCgAgACAACTTTCCCTT-30 and E6-377R 50-gCgTg-
CCTTTCCCAATATgTgC-30 (Table 1). A protocol of 50 cycles
of PCR amplification was performed at 95C for 5 seconds,
58C for 10 seconds, and 72C for 10 seconds usingion plots of serially diluted HPV-6 corresponding to an input of
l copies per assay. Values on the y-axis show the fluorescence
188 C.-F. Tai et al.LightCycler RNA Amplification Kit SYBR Green I (Roche) and
carried out in LightCycler 1.5 (Roche).
Nest PCR conditions
The assay was performed in two steps, including first round
and second round PCR. The first round PCR was designed to
amplify the common sequence of HPV-6 and HPV-11 E6 gene.
The second round PCR was designed to identify the specific
sequence of HPV-6 and HPV-11, respectively, within the first
PCR product. The first round primers were HPV6&11-E6-35F
(50 CYATAgACCAgTTgTgCAAg 30) and HPV6&11-E6-431R (50
CATgCATgTTgTCCAgCAgTgT 30). The second round primers
were the same primers used in real-time PCR, as described
earlier (Table 1). The visualization of the amplified product
was carried out using electrophoresis with 2% agarose gel
(Onestar, Taiwan).Results
Detection limits and sensitivities of real-time
PCR assays
The fluorescence values versus cycle number are displayed
in Figs. 2 and 3. 4 101 copies of the DNA of HPV-6 can be
reproducibly detected after 33.47 cycles of real-time PCR.Figure 3. The standard curve of HPV11 real-time PCR. Amplificat
4 107, 4 106, 4 105, 4 104, 4 103, 4 102, and 4 101 vira
dependent on the PCR cycle number on the x-axis.The assay detected the same concentration of HPV-11 at
34.25 cycles.
Melting curve analysis
Melting curve analysis of the PCRproducts identified aunique
melting peak for HPV-11 and HPV-6 genomic variants,
allowing for unambiguous differentiation. The prototypic
HPV-6 variant showed a specific melting peak at 83C, and
HPV-11 showed a specific melting peak at 81.5C (Fig. 4).
The electrophoresis of real-time PCR and nest-PCR
All positive specimens were visible with gel electrophoresis
and southern blot hybridization. Six positive signals were
detected in 108 clinical specimens by real-time PCR; five
were HPV-11 and one was HPV-6. The nested PCR revealed
two more samples with positive sequences of HPV-11. Fig. 5
shows the typical PCR reaction profiles of HPV-11. The
figure also shows the positive nested PCR of HPV-11 and the
specific sequence (PPH11).
Clinical manifestation
HPV-DNA was detected from respiratory secretion in eight
of the 108 newborns who underwent intubation soon after
birth. One carried HPV-6 and 7 carried HPV-11. The medianion plots of serially diluted HPV-11 corresponding to an input of
l copies per assay. Values on the y-axis show the fluorescence
Figure 4. The real-time PCR melting curve of HPV6 and 11. Melting curve analysis detected amplicons of real-time PCR by SYBR
green. Two separately generated melting peaks were separated from the dissociation curve of amplicons. Values on the y-axis
represent the ratio of the first negative derivative of the change in fluorescence to the variation in temperature.
Molecular detection/epidemiology of HPV in neonates 189gestation age was 36 weeks. Of the 108 newborns, 77 were
born via Cesarean section.
All the patients with positive HPV result were intubated
due to respiratory distress. Six patients had underlying
disease including congenital anomaly, trisomy 13, tetralogy
of Fallot, transposition of the great arteries, and biliary
atresia. Three patients died of underlying diseases. No
stridor was noted in any of the five surviving children during
the first 2 years of their life; four patients were born via
normal spontaneous delivery, and the other four were born
via Caesarean section. No genital condyloma was found in
any of their mothers before delivery (Table 2).Discussion
Recent studies have confirmed that HPV may be passed by
vertical transmission from mother to child. Renato and
others11 suggested that perinatal transmission of HPV-DNA
occurred in 24.5% of delivery. Gajewska and colleagues12
detected a high rate (70%) of HPV transmission from
mother to neonate. HPV DNA has been detected in amniotic
fluid, cord blood, and fetuses. These studies demonstrated
that the virus can infect children during the perinatal
period.5,13e15 In addition to vertical transmission, hori-
zontal spread of HPV can occur from other family
members and those in close contact with the child. Marjut
and colleagues16 presented a prospective study abouttransmission of high-risk HPV between the parents and
infant. The study showed that a persistent presence of HPV
in the cervix and oral cavity of a mother was associated
with a risk of HPV infection of the infant.
In our study, after analyzing samples of tracheal aspirate
within the first 30 days of birth, it was observed that eight
neonates (7.4%) tested positive for HPV-DNA. This is the
first study to evaluate neonatal HPV carriage in Taiwan. The
acquisition of HPV DNA was likely vertical from mothers.
This study also showed the efficacy of the multiple meth-
odology in HPV DNA detection with real-time PCR and nest
PCR, eliminating false-negative results.
The real-time PCR method has a number of advantages
over the assays for HPV-6 and HPV-11. The assay has high
sensitivity and specificity. The primers were designed on
the basis of HPV-6 and HPV-11 E2 sequences, and the assay
is considered to be capable of recognizing the broadest
spectrum of genomic variants of HPV-6 and HPV-11.
The HPV transmission is including sexual transmitted
route, close personal contact with skin or mucus, and noso-
comial transmission. Close personal contact is an important
transmission route of cutaneous warts, and nosocomial
transmission may result from fumes with the infectious virus
released from lesion during treatment with carbon dioxide
laser or electrocoagulation. The neonates in our study were
all intubated due to underlying disease. The specimens
were collected from tracheal aspirate. The transmitted route
was not above the three routes. Thereafter, perinatal
Figure 5. Electrophoresis of the amplified HPV11 DNA in some of the cytologic samples of this study. (A) In real-time PCR,
amplified products are checked by electrophoresis using 2% argarose gel. Lane1, 100bp DNA molecular marker (onestar, Taiwan);
the last lane is positive control (PC). The positive patient numbers are 18, 38, 40, 48 and 57. (B) The other two positive reactions
were determined by nest-PCR (no. 18 and 49). (C)Two nest-PCR positive amplified HPV11 DNA samples were sequenced and
compared with known HPV sequence (accession number: PPH11).
190 C.-F. Tai et al.transmission was the main route of our patients. Because
all of our study participants were admitted to neonatal
intensive care unit soon after birth, the transmission route
appears to be passage through birth canal or ascending
infection. At this point, the route of HPV vertical transmissionTable 2 Clinical manifestation of neonates with HPV colonizat
Gestation age (weeks) Delivery route Und
Case 1 39 C/S Bilar
Case 2 37 C/S Peri
Case 3 38 NSD Tetr
Case 4 38 NSD Cong
Case 5 33 C/S Tran
Case 6 37 C/S Tran
Case 7 29 NSD Peri
Case 8 34 NSD Prem
NSD: normal spontaneous delivery; C/S: Cesarean-section delivery.remains unclear. The routes may exist during pregnancy
(transamniotic ascending infection), during labor (ascending
infection after the amniotic membranes are ruptured), or
during delivery (by the fetus passing through a contaminated
birth canal).3 In our study, four (50%, nZ 4/8) patients wereion
erlying disease HPV type Prognosis
y atresia 11 Survival
natal asphyxia 11 Survival
alogy of Fallot 11 Survival
enital anomaly 11 Death
sposition of the Great Arteries 11 Death
sposition of the Great Arteries 11 Survival
nal asphyxia 11 Death
aturity 6 Survival
Molecular detection/epidemiology of HPV in neonates 191born via normal spontaneous delivery and four patients (50%,
nZ 4/8) were born via Caesarean section. The transmission
routes of those born via normal spontaneous delivery
included transamniotic ascending infection, ascending
infection after the amnioticmembraneswere ruptured, or by
the fetus passing through a contaminated birth canal. The
transmission routes of those born via Caesarean section
included all ascending infection routes and excluded the
possibility of a contaminated birth canal. These results
emphasize that there may be more transmission routes via
ascending infection in comparison with a contaminated birth
canal. The patient group and specimens differed from other
studies; in other studies, specimens were collected from
nasopharyngeal aspirate, the surface of the body, genital
organs, or arterial blood taken from the umbilical cord.3,11
The presence of HPV in tracheal aspirate signifies that it
can colonize in the trachea via the mother-child vertical
transmission. In our study, three patients were premature,
and the relationship between maternal HPV infection and
neonatal prematurity remains unclear. Mammas and
colleagues17 provided maternal HPV infection that may be
related to neonatal prematurity.
Colonization of HPV in newborns may result in later
respiratory papillomatosis and an increased risk of carci-
nogenic potential. The virus primarily infects epithelial
cells. RRP has a variable incubation period, which may be as
short as several weeks or as long as several years. It may
develop to the subclinical form or reactivate, leading to
chromosomal mutations in host cells. The result after this
accumulated latent carcinogenic potential of certain types
of HPV during childhood would be the development of
neoplasm for life. The natural history of papillomavirus
infection is characterized by regression in a period that
varies from months to years.3,18 In our study, none of the
surviving neonates with HPV colonization progressed to
RRP. This may have been due to the relatively small amount
of cases and short follow-up period.
Currently, two HPV prophylactic vaccines have been
developed successfully: quadrivalent and bivalent HPV
vaccines. Both vaccines provide protection against persis-
tent infection with high-risk HPV-16 and 18. The quadriva-
lent HPV vaccine also provides prevention for HPV-6-related
and HPV-11-related genital warts and juvenile-onset
recurrent respiratory papillomatosis.19e22 The vaccine has
no effect on pre-existing genital infections or lesions, but it
prevents new genital infections through one of the four
vaccine types as well as the epithelial lesions induced by
them. Pawlita and colleagues23 hypothesize that HPV
vaccination could have a therapeutic effect in RRP by
preventing new papilloma formations at additional sites.
Erik and colleagues24 showed that a quadrivalent HPV
vaccination program in Hungary could reduce the incidence
of cervical cancer, cervical intraepithelial neoplasia, and
genital warts. The cost-per-QALY ratio within the range was
defined as cost effective. Jane and others25 suggest that
the cost-effectiveness of HPV vaccination will depend on
the duration of vaccine immunity and will be optimized by
achieving high coverage in preadolescent girls, closing the
gap among nonvaccinated women younger than 21 years of
age, and revising screening policies.
To conclude, eight neonates were detected as having
HPV from tracheal aspirate. No clinical symptoms ofpersistent hoarseness or stridor were noted after extuba-
tion, signifying that these patients had HPV colonization in
the trachea. Neonates with HPV colonization may be asso-
ciated with juvenile-onset recurrent respiratory papil-
lomatosis. The route of neonate HPV infection may be
through a vertical transmission from mother to child. Our
study revealed a 7.4% infection rate by ascending and
passage through the birth canal. To prevent vertical
transmission of HPV, targeted immunization may be an
effective strategy. Real-time PCR assay has proven its value
for clinical and epidemiologic studies of HPV-6 and HPV-11
infections.
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